A5021604018- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Microscopic Colitis
- Inflammatory Bowel Disease
- Colorectal Cancer Treatments and Studies
- Tracheal and airway disorders
- Helicobacter pylori-related gastroenterology studies
- Autoimmune and Inflammatory Disorders
- Neuroendocrine Tumor Research Advances
- Liver Disease Diagnosis and Treatment
- Lung Cancer Research Studies
- Gastroesophageal reflux and treatments
- Bladder and Urothelial Cancer Treatments
- Esophageal Cancer Research and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Sarcoidosis and Beryllium Toxicity Research
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Hepatitis Viruses Studies and Epidemiology
- Bone health and treatments
- Pancreatitis Pathology and Treatment
- Traditional Chinese Medicine Studies
- Gastrointestinal disorders and treatments
- Liver Diseases and Immunity
- Renal and related cancers
Fundación Chile
2024-2025
Fundación Valle del Lili
2018-2024
Vall d'Hebron Hospital Universitari
2023
Mayo Clinic in Arizona
2022
Complejo Hospitalario de Navarra
2019
Navarre Institute of Health Research
2019
Universidad del Valle
2019
University of Caldas
2005
440 Background: The phase 1/2 KEYMAKER-U03 Substudy 03B (NCT04626518) is being conducted to evaluate combination treatments for previously treated advanced ccRCC. We present results targeted therapy–containing regimens from arm B4 (pembro + belzutifan [HIF-2α inhibitor]), B5 (lenvatinib [VEGF-TKI] belzutifan), and the reference (ref) lenvatinib). Methods: Adults with histologically confirmed locally advanced/metastatic ccRCC disease progression on or after PD-(L)1 inhibitor VEGF-TKI...
LBA358 Background: CheckMate 914 (NCT03138512) is a phase 3, randomized, double-blind, multicenter, 2-part trial evaluating adjuvant NIVO plus ipilimumab (NIVO+IPI) vs PBO (Part A) or monotherapy (and NIVO+IPI to assess the contribution of components; Part B) designed in sequence mutually exclusive patients (pts) with localized RCC at high risk post-nephrectomy relapse. Results from A 37.0 months median study follow-up (range, 15.4–58.0) showed no disease-free survival (DFS) benefit for...
552 Background: Substudy 03B of the phase 1/2 KEYMAKER-U03 trial (NCT04626518) was designed to evaluate combination treatments with pembro and investigational agents for previously treated ccRCC. We present results from arms containing only immunotherapy regimens: arm B1 (quavonlimab [qmab; anti–CTLA-4] coformulated pembro), B2 (favezelimab [fave; anti–LAG-3] B3 (pembro + MK-4830 [anti-ILT4]), reference (ref) lenvatinib). Methods: Adults histologically confirmed ccRCC disease progression on...
PURPOSE CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or monotherapy B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for placebo. We report results from part B. METHODS Patients were randomly assigned (2:1:1) to (240 mg once every 2 weeks up 12 doses), placebo, doses) (1 mg/kg 6...
411 Background: LEAP-015 (NCT04662710) is a randomized, open-label, 2-part, phase 3 study of the safety and efficacy lenvatinib + pembrolizumab chemotherapy as first-line treatment for advanced/metastatic gastroesophageal adenocarcinoma. We report findings from part 1, run-in, LEAP-015. Methods: Eligible patients had untreated, HER2-negative, locally advanced unresectable or metastatic adenocarcinoma, measurable disease per RECIST v1.1, ECOG performance status 0 1. In received induction with...
The COVID-19 pandemic has highlighted the need for rapid and accurate tests to detect SARS-CoV-2. Objectives: This study evaluates effectiveness of Panbio™ Antigen Self-Test test compared reverse transcriptase polymerase chain reaction (RT-PCR). Methods: A prospective diagnostic testing was performed. Patients with respiratory symptoms who provided informed consent were included. Results: We included 205 patients underwent both tests. mean age 35.55 ± 12.62 years, 64% participants female....
8605 Background: MK-1084 is an oral, next-generation, selective KRAS G12C-GDP covalent inhibitor. The phase 1 KANDLELIT-001 study (NCT05067283) showed manageable safety and antitumor activity for monotherapy in G12C-mut solid tumors + pembrolizumab (pembro) mNSCLC. We report additional NSCLC preliminary ctDNA data from this study. Methods: Pts had confirmed G12C-mut, RECIST-measurable disease ECOG PS 0-1. with any advanced tumor ≥1 prior systemic therapy received 25-800 mg/d arms 3....
e13135 Background: First-line treatment for advanced TNBC with PD-L1 CPS ≥10 is chemotherapy plus pembro. ILT3 an inhibitory receptor expressed on monocytic myeloid cells. High expression associated immune tolerance and suppression of T-cell function. MK-0482 anti-ILT3 mAb hypothesized to relieve immunosuppression improve function within the tumor microenvironment. Safety efficacy data from a dose expansion cohort first-in-human, phase 1 MK-0482-001 study (NCT03918278) evaluating in...
TPS232 Background: Mutations in KRAS are one of the most prevalent oncogene mutations human cancers, among which G12C frequently occurring. inhibitors can slow tumor growth via attenuation signaling pathway. MK-1084, a selective inhibitor, has demonstrated promising antitumor activity preclinical studies. This phase 1, open-label, multicenter study (ClinicalTrials.gov, NCT05067283) is first MK-1084 clinical and aims to evaluate it as monotherapy combination therapy patients (pts) with...
Introducción: La hepatitis autoinmune (HAI) es una enfermedad inflamatoria crónica del hígado. Es entidad que no se puede considerar infrecuente, por la falta de datos epidemiológicos, poco reconocida y tiene implicaciones en el riesgo aparición hepática avanzada; así mismo, los clínicos, muchas veces detecta estadios avanzados. El objetivo éste estudio describir las características sociodemográficas, clínicas laboratorio, como, tratamientos recibidos respuesta a éstos, desenlaces interés...
Introducción: la pancreatitis aguda (PA) es una enfermedad de alta complejidad clínica y, acuerdo con sugravedad, puede tener elevada morbimortalidad altos costos para el sistema salud, especialmente a nivel intrahospitalario.
 Materiales y métodos: se desarrolló un estudio descriptivo basado en historias clínicas hospital universitario complejidad. Se revisaron las diagnóstico CIE 10 entre enero 2011 diciembre 2018. incluyeron todos los pacientes mayores 18 años, ambos sexos, PA por...
Introducción: la infección por Helicobacter pylori tiene una alta prevalencia y distribución a nivel mundial. Por su asociación con el desarrollo de adenocarcinoma gástrico, las actualizaciones sobre son interés para médico internista o gastroenterólogo, así como generación políticas públicas. Este estudio midió H. evaluó hallazgos endoscópicos e histopatológicos en adultos indicación endoscopia vías digestivas altas (EVDA). Metodología: cohorte analítica describir evaluar factores riesgo...
CYP2C19 is a highly polymorphic gene that encodes an enzyme with the same name and whose function associated metabolism of many important drugs, such as proton pump inhibitors (such esomeprazole, which used for treatment acid peptic disease). Genetic variants in alter protein affect drug metabolism. This study aims to genotypically phenotypically characterize genetic 12 patients disorders different therapeutic profiles inhibitor (PPI) drugs. The were randomly selected from controlled,...
e20600 Background: Immunotherapy has changed the landscape for small cell lung cancer treatment. The aim of this study was to evaluate efficacy durvalumab plus chemotherapy in (SCLC) patients real world experience. Methods: Eligibility criteria included, histologically confirmed extended stage SCLC (ES-SCLC), evaluable disease and no prior therapy. Patients received until progressive (PD) or unacceptable toxicity. main report safety profile with our everyday clinical practice. secondary...
Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts been made identify effective strategies, mostly negative results. However, recent results immune checkpoint inhibitors change current standard, several ongoing trials are exploring new alternatives. In this perspective, we aim provide an overview previous adjuvant therapy efforts, data supporting...
Introducción: en Colombia, la infección por el virus de hepatitis C (VHC) representa alta morbilidad y elevados costos. Con llegada nuevos tratamientos más efectivos, se hace necesario conocer las características propias esta población para su adecuado uso.Objetivos: describir epidemiológicas clínicas los pacientes con VHC manejados un centro referencia enfermedades hepáticas.Materiales métodos: realizó estudio descriptivo corte transversal una adultos diagnóstico serológico entre 2011...
Introducción: en América Latina, la enfermedad inflamatoria intestinal (EII) es poco frecuente y información, limitada. Se describieron características de los pacientes con EII una unidad gastroenterología clínica alto nivel atención Cali, Colombia.
 Materiales métodos: estudio descriptivo que consultaron diagnóstico Crohn (EC) o colitis ulcerativa (CU) a Clínica Fundación Valle del Lili entre enero 2011 diciembre 2015. realizó un análisis Statistical Package for the Social Sciences IBM...
Introducción y objetivos: confirmar la erradicación de Helicobacter pylori es esencial debido al aumento resistencia antimicrobiana a diferentes esquemas tratamiento. El objetivo principal del estudio determinar el porcentaje H. por medio prueba aliento con carbono 14 (14C). Materiales métodos: se realizó un transversal componente analítico, recolección retrospectiva información mediante revisión historias clínicas pacientes que recibieron tratamiento erradicador para tuvieron una posterior...
TPS425 Background: Initial signal finding studies demonstrated promising antitumor activity with the anti–PD-1 antibody pembrolizumab in combination anti-angiogenic multikinase inhibitor lenvatinib patients advanced gastric cancer or head and neck squamous cell carcinoma. Because hypoxia is common many solid tumors known to induce an immunosuppressive tumor microenvironment, targeting hypoxia-inducible factor-2 alpha (HIF-2α) may enhance of immune checkpoint inhibitors. The ongoing phase 2...
Abstract Background: Pembrolizumab (pembro) plus chemotherapy (chemo) is an approved therapy for patients (pts) with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) based on results from KEYNOTE-355. However, there unmet need effective treatment options in pts CPS <10. In a first-in-human, open-label, phase 1 study (NCT03396445), escalating doses of the humanized anti-CD27 agonist boserolimab (MK-5890) alone and pembro had acceptable safety...
Introducción: la calidad de colonoscopia es un factor determinante en los desenlaces clínicos y depende gran medida limpieza intestinal lograda con una adecuada preparación. El tipo agente, adherencia tolerabilidad son factores que pueden influenciar y, por ende, resultados del procedimiento. Con este estudio se busca evaluar cuáles motivos determinan escogencia agente para preparación su impacto colonoscopia. Metodología: observacional corte transversal muestra 530 pacientes. Agentes...